Platelet function and pharmacologic inhibition

Vascular and Endovascular Surgery

Volumn 40, Issue 4, 2006, Pages 261-267

  Chaer, Rabih A ^a   Graham, Joseph A ^b   Mureebe, Leila ^a,c  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b University of Missouri   (United States)

^c NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARACHIDONIC ACID; ARGATROBAN; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; CALCIUM; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN; FIBRONECTIN; HEPARIN; HIRUDIN; HIRULOG; LAMININ; PHOSPHOLIPASE C; PLATELET DERIVED GROWTH FACTOR; PYROPHOSPHATE; SEROTONIN; THROMBOCYTE FACTOR 4; THROMBOCYTE RECEPTOR; THROMBOSPONDIN; THROMBOXANE A2; TICLOPIDINE; UNINDEXED DRUG; VITRONECTIN; VON WILLEBRAND FACTOR;

ACUTE CORONARY SYNDROME; ACUTE PHASE RESPONSE; ANTICOAGULATION; ANTIMICROBIAL ACTIVITY; ATHEROSCLEROSIS; BERNARD SOULIER DISEASE; BLEEDING DISORDER; BLOOD CLOTTING; CLINICAL PRACTICE; DEATH; ELECTRON MICROSCOPY; FIBRINOLYSIS; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMOSTASIS; HOST RESISTANCE; HUMAN; INFLAMMATION; PERCUTANEOUS CORONARY INTERVENTION; RESTENOSIS; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOSIS; TUMOR GROWTH;

ANGIOPLASTY; ANIMALS; ANTIBODIES, MONOCLONAL; ASPIRIN; BLOOD COAGULATION; BLOOD PLATELETS; GRAFT OCCLUSION, VASCULAR; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET MEMBRANE GLYCOPROTEINS; THROMBOSIS; TICLOPIDINE;

EID: 33749037988     PISSN: 15385744     EISSN: None     Source Type: Journal    
DOI: 10.1177/1538574406291794     Document Type: Review

References (28)

1. Kaushansky K: Thrombopoietin: The primary regulator of megakaryocyte and platelet production. Thromb Haemost 74:521-525, 1995.
2. Wagner DD, Burger PC: Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol 23:2131-2137, 2003.
3. Phillips DR, Agin PP: Platelet plasma membrane glycoproteins. Evidence for the presence of nonequivalent disulfide bonds using nonreduced-reduced two-dimensional gel electrophoresis. J Biol Chem 252:2121-2126, 1977.
4. Shattil SJ, Newman PJ: Integrins: Dynamic scaffolds for adhesion and signaling in platelets. Blood 104:1606-1615, 2004.
5. French DL, Seligsohn U: Platelet glycoprotein IIb/IIIa receptors and Glanzmann's thrombasthenia. Arterioscler Thromb Vasc Biol 20:607-610, 2000.
6. Gibbins JM: Platelet adhesion signalling and the regulation of thrombus formation. J Cell Sci 117:3415-3425, 2004.
7. Bouchard BA, Tracy PB: Platelets, leukocytes, and coagulation. Curr Opin Hematol 8:263-269, 2001.
8. Parsson H, Norgren L, Ivancev K, et al: Thrombogenicity of metallic vascular stents in arteries and veins - an experimental study in pigs. Eur J Vasc Surg 4:617-623, 1990.
9. Farb A, Sangiorgi G, Carter AJ, et al: Pathology of acute and chronic coronary stenting in humans [see comment]. Circulation 99:44-52, 1999.
10. Ishiwata S, Tukada T, Nakanishi S, et al: Postangioplasty restenosis: Platelet activation and the coagulation-fibrinolysis system as possible factors in the pathogenesis of restenosis. Am Heart J 133:387-392, 1997.
11. Antithrombotic Trialists C: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients [see comment] [Erratum appears in BMJ 19;324:141, 2002]. BMJ 324:71-86, 2002.
12. Catella-Lawson F: Vascular biology of thrombosis: Platelet-vessel wall interactions and aspirin effects. Neurology 57:S5-7, 2001.
13. Kastrati A, von Beckerath N, Joost A, et al: Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation 110:1916-1919, 2004.
14. Caplain H: Enhanced antiplatelet effects of clopidogrel plus acetylsalicylic acid compared with acetylsalicylic acid alone or combined with extended-release dipyridamole in healthy volunteers. Cerebrovasc Dis 19:214-219, 2005.
15. Claeys MJ, Van der Planken MG, Bosmans JM, et al: Does pretreatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on periprocedural myonecrosis. Eur Heart J 26:567-575, 2005.
16. Kong D, Califf R, Miller D, et al: Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 98:2829-2835, 1998.
17. Coller B: A new murine monoclonal antibody reports an activation-dependent change in the confirmation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest 76:101-108, 1985.
18. Schneider PA: Endovascular Skills, ed 2. New York: Marcel Dekker, Inc, 2003, pp 209-210.
19. Shammas NW: Complications in peripheral vascular interventions: Emerging role of direct thrombin inhibitors. J Vasc Intervent Radiol 16:165-171, 2005.
20. Bush RL, Lin PH, Mureebe L, et al: Routine bivalirudin use in percutaneous carotid interventions. J Endovasc Ther 12:521-522, 2005.
21. Chew DP, Lincoff AM, Gurm H, et al: Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). Am J Cardiol 95:581-585, 2005.
22. Schussler JM, Cameron CS, Anwar A, et al: Effect of bivalirudin on length of stay in the recovery area after percutaneous coronary intervention compared with heparin alone, heparin + abciximab, or heparin + eptifibatide. Am J Cardiol 94:1417-1419, 2004.
23. Harker LA, Marzec UM, Kelly AB, et al: Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates. Circulation 98:2461-2469, 1998.
24. Chan AW, Moliterno DJ, Berger PB, et al: Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: Results from the Do tirofiban and reopro give similar efficacy outcome trial (TARGET). J Am Coll Cardiol 42:1188-1195, 2003.
25. Lee SW, Park SW, Hong MK, et al: Comparison of cilostazol and clopidogrel after successful coronary stenting. Am J Cardiol 95:859-862, 2005.
26. Thebault JJ, Kieffer G, Cariou R: Single-dose pharmacodynamics of clopidogrel. Semin Thromb Hemost 25(suppl 2):3-8, 1999.
27. Thebault JJ, Kieffer G, Lowe GD, et al: Repeated-dose pharmacodynamics of clopidogrel in healthy subjects. Semin Thromb Hemost 25(suppl 2):9-14, 1999.
28. Nguyen TA, Diodati JG, Pharand C: Resistance to clopidogrel: A review of the evidence. J Am Coll Cardiol 45:1157-1164, 2005.